ComplianceOnline

FDA Issues Guidance on Warning and Precautions Labeling for Drugs and Biological Products

  • By: Staff Editor
  • Date: November 11, 2011
Webinar All Access Pass Subscription Abstract:

In October 2011, the FDA issued final guidance on Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Prescription Drugs and Biological Products. The aim of the guidance is to help ensure that labeling is clear, useful, informative, and to the extent possible, consistent in content and format.

This article gives a brief overview and summary of the recommendations contained in the guidance.
 

Bookmark and Share

Compliance Trainings

Cleaning Validation Swab Recovery Studies and Analysis
By - Keith Bader
On Demand Access Anytime
Transfer of Analytical Methods According to the USP Chapter <1224>
By - Dr. Ludwig Huber
On Demand Access Anytime
4-Hour Virtual Training: Auditing the Microbiology Laboratory
By - Robert D Seltzer
On Demand Access Anytime

Compliance Standards

Best Sellers
You Recently Viewed
    Loading